

Title (en)

4-, 6- O 7-HYDROXYINDOLES HAVING N-OXIDE GROUPS AND THE USE THEREOF AS THERAPEUTIC AGENTS

Title (de)

4-, 6- ODER 7-HYDROXYINDOLE MIT N-OXIDGRUPPEN UND DEREN VERWENDUNG ALS THERAPEUTIKA

Title (fr)

4-, 6- OU 7-HYDROXYINDOLES A GROUPES N-OXYDE ET LEUR UTILISATION COMME PRODUITS THERAPEUTIQUES

Publication

EP 1615912 A1 20060118 (DE)

Application

EP 04729109 A 20040423

Priority

- EP 2004004338 W 20040423
- DE 10318611 A 20030424

Abstract (en)

[origin: WO2004094405A1] The invention relates to substituted 4-, 6- or 7-hydroxyindoles having N-oxide groups of formula (I), a method for the production thereof, pharmaceutical preparations comprising said compounds and the pharmaceutical use of said compounds which are inhibitors of phosphodiesterase 4, as active substances in the treatment of diseases which can be influenced by said inventive compounds by means of an inhibition of phosphodiesterase 4 activity, especially in immunocompetent cells (for example, macrophages and lymphocytes).

IPC 1-7

C07D 401/12; **A61K 31/4439**; **A61P 11/00**

IPC 8 full level

A61P 11/00 (2006.01); **C07D 401/12** (2006.01)

CPC (source: EP KR US)

A61P 1/00 (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/02** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/00** (2017.12 - EP); **A61P 13/02** (2017.12 - EP); **A61P 13/08** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 25/30** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 31/18** (2017.12 - EP); **A61P 33/00** (2017.12 - EP); **A61P 33/06** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 401/12** (2013.01 - EP KR US)

Citation (search report)

See references of WO 2004094405A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2004094405 A1 20041104; AR 044081 A1 20050824; AU 2004232482 A1 20041104; BR PI0409793 A 20060530; CA 2523048 A1 20041104; CN 1777600 A 20060524; DE 10318611 A1 20041111; EP 1615912 A1 20060118; JP 2006524208 A 20061026; KR 20060021831 A 20060308; MX PA05011437 A 20051212; NO 20055517 D0 20051122; NO 20055517 L 20060118; RU 2005136431 A 20060320; TW 200503693 A 20050201; US 2004242643 A1 20041202; US 2006128758 A1 20060615; US 7067536 B2 20060627; ZA 200507258 B 20060628

DOCDB simple family (application)

EP 2004004338 W 20040423; AR P040101396 A 20040423; AU 2004232482 A 20040423; BR PI0409793 A 20040423; CA 2523048 A 20040423; CN 200480011034 A 20040423; DE 10318611 A 20030424; EP 04729109 A 20040423; JP 2006505245 A 20040423; KR 20057020097 A 20051021; MX PA05011437 A 20040423; NO 20055517 A 20051122; RU 2005136431 A 20040423; TW 93111114 A 20040421; US 34242806 A 20060130; US 82586204 A 20040416; ZA 200507258 A 20050909